Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003), a Long-acting cAMP Signaling Biased GLP-1 Analog, in Adult Patients with Type 2 Diabetes in China ...Middle East

Study participants receiving 0.6 and 1.2 mg ecnoglutide once weekly for 24 weeks achieved HbA1c reductions of 1.96 and 2.43% from baseline, respectively, compared to 0.87 % for placebo In the 1.2 mg ecnoglutide cohort, 76.1% of participants achieved HbA1c ≤ 6.5% and 35.2% achieved HbA1c

Read More Details
Finally We wish PressBee provided you with enough information of ( Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003), a Long-acting cAMP Signaling Biased GLP-1 Analog, in Adult Patients with Type 2 Diabetes in China )

Also on site :

• Adidas Has 'Sleek' $180 Running Shoes for Just $90, and Reviewers Say They Feel Like They’re 'Walking On Clouds'
• UNHCR: 2.5M refugees need resettlement as US freezes program
• Legendary '60s Rock Band Released a Song 45 Years Ago That Led to Their Split